Citations

Clear

1011 citation(s) found for "Barry, WT".

Conversation: Beyond black boxes: tackling artificial intelligence as a design material
Berzowska, Joanna, O'Murchu, Nora, Kelliher, Aisling , Barry, Barbara , Smeaton, Alan F.

Mayo Clinic

Proceedings of DRS | March 16, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21606/drs.2018.784 Get It

A model-based approach to dose optimization of neurotoxic chemotherapy for metastatic breast cancer (MBC).
Gray, Elizabeth, Mehrotra, Shailly , Wu, Kehua, Barry, William T., Hudis, Clifford A. , Lyss, Alan P., Toppmeyer, Deborah , Moreno‐Aspitia, Alvaro , Ratain, Mark J. , Sharma, Manish R. , Gray, Elizabeth, Winer, Eric P. , Rugo, Hope S. , Gobburu, Jogarao

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 1041-1041

10.1200/jco.2015.33.15_suppl.1041 Get It

Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques
Matchett, William E. , Anguiano-Zarate, Stephanie S., Shelton, Kathryn A. , Nehete, Bharti P. , Yang, Guojun , Dorta‐Estremera, Stephanie , Barnette, Philip , Xiao, Peng , Villinger, François , Hessell, Ann J. , Haigwood, Nancy L. , Barry, Michael A. , Barry, Michael A , Nehete, Pramod N. , Byrareddy, Siddappa N. , Sastry, K. Jagannadha

Mayo Clinic

Journal of Virology | March 4, 2019 | Volume: 93 | Issue: 10 | Pages: No page available

10.1128/jvi.02016-18 | PMID 30842321 Get It

HIV-1 infections usually start at a mucosal surface after sexual contact. Creating a barrier of protection at these mucosal sites may be a good strategy for to protect against HIV-1 infections. While HIV-1 enters at mucosa, most vaccines are not delivered here. Most are instead injected into the muscle, a site well distant and functionally different than mucosal tissues. This study tested if delivering HIV vaccines at mucosa or in the muscle makes a difference in the quality, quantity, and location of immune responses against the virus. These data suggest that there are indeed advantages to educating the immune system at mucosal sites with an HIV-1 vaccine.
Low‐Gradient Severe Mitral Stenosis: Hemodynamic Profiles, Clinical Characteristics, and Outcomes
Sabbagh, Abdallah El , Reddy, Yogesh N.V. , Barros‐Gomes, Sergio , Borlaug, Barry A. , Miranda, William R. , Pislaru, Sorin V. , Pellikka, Patricia A. , Sabbah, Michael S. , Nishimura, Rick , Pellikka, Patricia A , Borlaug, Barry A , Nishimura, Rick A.

Mayo Clinic

Journal of the American Heart Association | February 22, 2019 | Volume: 8 | Issue: 5 | Pages: No page available

10.1161/jaha.118.010736 | PMID 30793648 Get It

Background Optimal management of patients with severe mitral stenosis ( MS ) and low transmitral gradient is incompletely understood. Methods and Results We examined 101 consecutive patients with severe rheumatic MS (mitral valve area ≤1.5 cm 2 ) who underwent balloon valvuloplasty. Low gradient was defined as mean transmitral gradient <10 mm Hg and low flow as stroke volume index ≤35 mL/m 2 by echocardiography. Symptoms and mortality data were collected. Systolic, diastolic, and arterial function were characterized by measuring left ventricular (LV) end‐systolic elastance, LV stiffness constant (β), diastolic capacitance (predicted LV end‐diastolic volume at a common LV filling pressure of 30 mm Hg), and effective arterial elastance. Low gradient (<10 mm Hg) was present in 55 patients, including low flow/low gradient in 11 and normal flow/low gradient in 44 patients, and high gradient was present in 46 patients. Participants with low‐flow/low‐gradient (LG) MS were older with higher rates of atrial fibrillation (64%) and subvalvular thickening, higher afterload, and decreased LV compliance with lower ejection fraction (57±10% versus 65±4% versus 63±6%, P =0.002) but similar end‐systolic elastance compared with patients with normal‐flow/ LG and high‐gradient MS . The normal‐flow/ LG group had larger mitral valve area and lower left atrial pressure by catheterization, as well as favorable long‐term outcomes compared with the low‐flow/ LG and high‐gradient MS group. A total of 40% of patients with LG MS had no symptomatic benefit from valvuloplasty compared with 18% of patients with high‐gradient MS ( P =0.02). Conclusions Presence of low gradient in patients with severe MS was associated with lesser symptomatic benefit from valvuloplasty. In the subset with low stroke volume index, this may be related to independent ventricular‐vascular uncoupling, decreased LV compliance, and high prevalence of atrial fibrillation in addition to intrinsic MS .
Response by Reddy and Borlaug to Letters Regarding Article, “A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction”
Reddy, Yogesh N.V. , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A

Mayo Clinic

Circulation | February 11, 2019 | Volume: 139 | Issue: 7 | Pages: 992-993

10.1161/circulationaha.118.038818 | PMID 30742532 Get It

Left Atrial Dysfunction: The Next Key Target in Heart Failure with Preserved Ejection Fraction
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

European Journal of Heart Failure | February 8, 2019 | Volume: 21 | Issue: 4 | Pages: 506-508

10.1002/ejhf.1420 | PMID 30734449 Get It

Abstract A062: Systemic oncolytic virotherapy for prostate cancer
Nguyen, Tien, Barry, Michael A.

Mayo Clinic

Cancer Research | February 4, 2019 | Volume: 78 | Issue: 16_Supplement | Pages: A062-A062

10.1158/1538-7445.prca2017-a062 Get It

Abstract Oncolytic viruses hold promise as “self-amplifying” cancer therapies wherein a virally killed cell can produce thousands of new viral “drugs” that can kill more cancer cells. Oncolytic viruses may also serve to reawaken or initiate immune responses against cancers by virtue of their abilities to lyse cells, liberate cancer antigens, and provide viral DNA and proteins as immune adjuvants. Oncolytics can also be armed with cytokine or checkpoint inhibitors to amplify antitumor immune responses. Adenoviruses (Ads) are one family of oncolytic viruses. Most human studies have used human Ad serotype 5 (Ad5). Unfortunately, most patients are already immune to Ad5, increasing the likelihood that the agent will be neutralized if used as a cancer therapy. In this work, low seroprevalence Ad6 and Ad57 oncolytic viruses were tested as intravenous therapies against distant prostate cancer sites. After prostate cell infection in vitro, Ad viruses executed these cells efficiently and generated 10,000 to 100,000 progeny infectious viruses. This genome replication also amplified transgene protein production by 100 to 1,000-fold when compared to nonreplicating Ad vectors. Ad5, Ad6, and Ad57 were injected intravenously a single time in nude mice bearing human prostate tumors, and toxicity and efficacy were assessed. Ad6 and 57 produced 30-fold lower liver damage and less toxicity than Ad5. Ad6 and Ad57 significantly repressed the growth of androgen-resistant human DU145 prostate tumors and androgen-sensitive LNCaP prostate tumors and extended survival after single intravenous injection in mice. Ad6 and Ad57 E1 protein were also modified to protect normal cells from viral oncolysis while allowing the virus to amplify and kill prostate cancer cells having perturbations in p300 and pRB pathways. These and other data suggest that targeted and untargeted low seroprevalent Ad6 and Ad57 have better efficacy and safety than the benchmark oncolytic virus Ad5 for systemic therapy of advanced prostate cancer. Citation Format: Tien Nguyen, Michael A. Barry. Systemic oncolytic virotherapy for prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A062.
A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study
Partridge, Ann H. , Ruddy, Kathryn J. , Barry, William T., Ligibel, Jennifer A. , Sprunck‐Harrild, Kim , Rosenberg, Shoshana M. , Baker, Emily, Hoverman, J. Russell , Emmons, Karen M. , Partridge, Ann H , Greaney, Mary L.

Mayo Clinic

Cancer | February 1, 2019 | Volume: 125 | Issue: 11 | Pages: 1799-1806

10.1002/cncr.31984 | PMID 30707756 Get It

Background The authors conducted a cluster randomized study to determine the effect of an exportable educational intervention for young women with breast cancer (YWI) on improving care. Methods Sites were randomized 1:1 to the YWI or a contact time control physical activity intervention (PAI) stratified by academic or community site. Up to 15 women aged ≤45 years with newly diagnosed breast cancer were enrolled at each of 14 academic sites and 10 were enrolled at each of 40 community sites. The primary endpoint, attention to fertility, was ascertained by medical record review. Statistical inferences concerning the effect of the intervention used general estimating equations for clustered data. Results A total of 467 patients across 54 sites were enrolled between July 2012 and December 2013. The median age of the patients at the time of diagnosis was 40 years (range, 22‐45 years). Attention to fertility by 3 months was observed in 55% of patients in the YWI and 58% of patients in the PAI ( P = .88). Rates were found to be strongly correlated with age ( P < .0001), and were highest in patients aged <30 years. Attention to genetics was similar (80% in the YWI and 81% in the PAI), whereas attention to emotional health was higher in patients in the YWI (87% vs 76%; estimated odds ratio, 2.63 [95% confidence interval, 1.20‐5.76; P = .016]). Patients rated both interventions as valuable in providing education (64% in the YWI and 63% in the PAI). Conclusions The current study failed to demonstrate differences in attention to fertility with an intervention to improve care for women with breast cancer, although attention to fertility was found to be higher than expected in both groups and emotional health was improved in the YWI group. Greater attention to young women with breast cancer in general may promote more comprehensive care for this population.
Haemodynamic Profiles in Adult Fontan Patients: Associated Haemodynamics and Prognosis
Miranda, William R. , Borlaug, Barry A. , Hagler, Donald J. , Connolly, Heidi M. , Egbe, Alexander C. , Borlaug, Barry A

Mayo Clinic

European Journal of Heart Failure | January 24, 2019 | Volume: 21 | Issue: 6 | Pages: 803-809

10.1002/ejhf.1365 | PMID 30672076 Get It

Abstract Aims The Fontan operation is associated with significant long-term morbidity and mortality, posing challenges in management. No haemodynamic classification has been established to aid management and prognostication of patients with Fontan palliation. Our aim was to assess haemodynamic profiles for Fontan patients and evaluate their relationships to prognosis. Methods and results Eighty-four adult Fontan patients without obstruction or significant valve disease undergoing cardiac catheterization for Fontan-related co-morbidities were divided into four different haemodynamic profiles based on normal/high Fontan pressures (FP) (&lt; 15 or ≥ 15 mmHg) and low/normal cardiac index (CI) (&lt; 2.5 or ≥ 2.5 L/min/m2). Fourteen patients had low CI/high FP (17%), 24 low CI/normal FP (29%), 20 normal CI/high FP (24%), and 26 normal CI/normal FP (31%). Demographic and clinical data were similar among groups except for a trend towards a higher prevalence of cirrhosis in the normal CI/high FP (50%) group. Systemic vascular afterload, assessed by systemic vascular resistance and effective arterial elastance, was higher in patients with low CI/high FP and low CI/normal FP as compared to normal CI profiles. Pulmonary vascular resistance indices were higher in patients with low CI/high FP than all other profiles. The normal CI/high FP haemodynamic profile was an independent predictor of mortality (hazard ratio 4.1, 95% confidence interval 1.2–11.5). Heterotaxy and protein-losing enteropathy were also predictors of mortality on the multivariate model. Conclusion The proposed haemodynamic classification provides prognostic information in adults post-Fontan with patients in the normal CI/high FP profile having worse survival. Whether this classification can guide management in these patients deserves further investigation.
The β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction
Reddy, Yogesh N.V. , Obokata, Masaru , Koepp, Katlyn E. , Egbe, Alexander C. , Wiley, Brandon M. , Borlaug, Barry A. , Wiley, Brandon, Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation Research | January 17, 2019 | Volume: 124 | Issue: 2 | Pages: 306-314

10.1161/circresaha.118.313832 | PMID 30582447 Get It

Rationale: Pulmonary vascular resistance fails to decrease appropriately during exercise in patients with heart failure with preserved ejection fraction (HFpEF). Interventions that enhance pulmonary vasodilation might be beneficial in this cohort but could also worsen left atrial hypertension, exacerbating lung congestion. Intravenous β-agonists reduce pulmonary vascular resistance but are not suitable for chronic use. Objective: We hypothesized that the inhaled β-adrenergic agonist albuterol would improve pulmonary vasodilation during exercise in patients with HFpEF, without increasing left heart filling pressures. Methods and Results: We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled albuterol on resting and exercise hemodynamics in subjects with HFpEF using high-fidelity micromanometer catheters and expired gas analysis. The primary end point was pulmonary vascular resistance during exercise. Subjects with HFpEF (n=30) underwent resting and exercise hemodynamic assessment and were then randomized 1:1 to inhaled, nebulized albuterol or placebo. Rest and exercise hemodynamic testing was then repeated. Albuterol improved the primary end point of exercise pulmonary vascular resistance as compared with placebo (−0.6±0.5 versus +0.1±0.7 WU; P =0.003). Albuterol enhanced cardiac output reserve and right ventricular pulmonary artery coupling, reduced right atrial and pulmonary artery pressures, improved pulmonary artery compliance, and enhanced left ventricular transmural distending pressure (all P <0.01), with no increase in pulmonary capillary hydrostatic pressures. Conclusions: Albuterol improves pulmonary vascular reserve in patients with HFpEF without worsening left heart congestion. Further study is warranted to evaluate the chronic efficacy of β-agonists in HFpEF and other forms of pulmonary hypertension. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02885636.